VolitionRx Limited APIC, Share-based Payment Arrangement, Recognition and Exercise
VolitionRx Limited (VNRX) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $103.57 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2026-03-31
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-03-31 was $103.57K.
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for the quarter ending 2023-06-30 was $592.17K, a 30.68% decline year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for the quarter ending 2023-03-31 was $693.66K, a 24.19% decline year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for the quarter ending 2022-09-30 was $639.08K, a 12.72% decline year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for fiscal 2025 was $103.57K.
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for fiscal 2022 was $3.11M, a 16.64% increase from fiscal 2021.
- VolitionRx Limited apic, share-based payment arrangement, recognition and exercise for fiscal 2021 was $2.67M.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month |
|---|---|---|---|---|
| 2025-12-31 | $103.57K 10-K · filed 2026-03-31 | |||
| 2025-03-31 | $103.57K 10-Q · filed 2025-11-13 | |||
| 2023-06-30 | $592.17K 10-Q · filed 2023-08-14 | $1.29M derived: sum of 2 quarters · filed 2023-08-14 | ||
| 2023-03-31 | $693.66K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $3.11M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $639.08K 10-Q · filed 2022-11-14 | $1.49M derived: sum of 2 quarters · filed 2023-08-14 | $2.41M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-06-30 | $854.30K 10-Q · filed 2023-08-14 | $1.77M derived: sum of 2 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $915.03K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $2.67M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $732.19K 10-Q · filed 2022-11-14 | $1.07M derived: sum of 2 quarters · filed 2022-11-14 | $1.63M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $337.74K 10-Q · filed 2022-11-14 | $893.09K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $555.34K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |